Glucagon-receptor-antagonism-mediated β-cell regeneration as an effective anti-diabetic therapy

Area of Science:

• Endocrinology
• Immunology
• Regenerative Medicine

Background:

• Type 1 diabetes mellitus (T1D) is characterized by beta-cell deficiency, leading to severe complications.
• Current therapies do not induce beta-cell regeneration in humans.
• Significant unmet need exists for therapies that restore beta-cell mass and function.

Purpose of the Study:

• To investigate the potential of glucagon receptor antibody (anti-GcgR) to induce beta-cell regeneration.
• To elucidate the mechanisms underlying anti-GcgR-mediated beta-cell regeneration.
• To evaluate the efficacy of anti-GcgR in preclinical models of diabetes.

Main Methods:

• Treatment of mouse models with beta-cell deficiency using anti-GcgR.
• Assessment of hyperglycemia, plasma insulin levels, and beta-cell mass.
• Investigation of beta-cell proliferation and alpha- to beta-cell transdifferentiation.
• Evaluation in non-human primate models and combination therapy with anti-CD3.

Main Results:

• Anti-GcgR treatment reversed hyperglycemia and increased insulin levels in mice.
• Restoration of beta-cell mass was observed, driven by proliferation and transdifferentiation.
• Anti-GcgR-induced beta-cell regeneration was confirmed in non-human primates.
• Combination therapy with anti-CD3 reversed diabetes and increased beta-cell mass in autoimmune diabetes models.

Conclusions:

• Glucagon receptor antibody (anti-GcgR) effectively induces beta-cell regeneration.
• Mechanisms include beta-cell proliferation and alpha- to beta-cell transdifferentiation.
• Anti-GcgR shows promise as a therapeutic strategy for type 1 diabetes in preclinical settings.